Login to Your Account

Not a One Size Fits All

Busy Schizophrenia Market, But Alkermes Presses On

By Brian Orelli
BioWorld Insight Contributing Writer

Tuesday, January 3, 2012

In spite of a market with numerous options for patients, Alkermes plc is pressing on with ALKS 9070, its long-lasting schizophrenia treatment. Last month the company started a Phase III trial testing the once-monthly drug in patients experiencing acute exacerbation of schizophrenia. (See BioWorld Today, Dec. 20, 2011.)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription